2-苄氧基-5-氯苯硼酸 | 612832-83-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-苄氧基-5-氯苯硼酸
• 中文别名: 2-苄氧基-5-氯苯基硼酸
• 英文名称: 2-benzyloxy-5-chlorophenylboronic acid
• 英文别名: (5-chloro-2-phenylmethoxyphenyl)boronic acid
• CAS: 612832-83-4
• 化学式: C₁₃H₁₂BClO₃
• mdl: MFCD04039000
• 分子量: 262.5
• InChiKey: SLERXVFZNNSBIX-UHFFFAOYSA-N

物化性质

• 熔点：
  108-110° C
• 沸点：
  462.3±55.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.68
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2931900090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
2-Benzyloxy-5-chlorophenylboronic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
2-Benzyloxy-5-chlorophenylboronic acid
Ingredient name:
CAS number: 612832-83-4

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C13H12BClO3
Molecular weight: 262.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-苄氧基-5-氯苯硼酸 在 sodium hydroxide 、 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 乙醇 、 甲苯 为溶剂， 生成 3-[2-(5-Chloro-2-phenylmethoxyphenyl)pyridin-3-yl]benzoic acid
  参考文献：
  名称：

  Discovery of novel biaryl heterocyclic EP1 receptor antagonists

  摘要：

  We describe the generation of novel EP1 receptor antagonists by investigation of thiophene isosteres. In addition, we disclose preliminary in vitro and in vivo DMPK for selected compounds. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.02.014
• 作为产物：
  描述：

  4-氯-2-碘苯甲醚, 在 盐酸 、 正丁基锂 、 三溴化硼 、 potassium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 、 丙酮 为溶剂， 生成 2-苄氧基-5-氯苯硼酸
  参考文献：
  名称：

  Discovery of novel biaryl heterocyclic EP1 receptor antagonists

  摘要：

  We describe the generation of novel EP1 receptor antagonists by investigation of thiophene isosteres. In addition, we disclose preliminary in vitro and in vivo DMPK for selected compounds. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.02.014

文献信息

• [EN] (2-((2-ALKOXY) -PHENYL) -CYCLOPENT-1-ENYL) AROMATIC CARBO AND HETEROCYCLIC ACID AND DERIVATIVES<br/>[FR] ACIDE (2-((2-ALCOXY) -PHENYL) -CYCLOPENT-1-ENYL) AROMATIQUE CARBOCYCLIQUE AND HETEROCYCLIQUE ET SES DERIVES
  申请人：GLAXO GROUP LTD

  公开号：WO2003084917A1

  公开（公告）日：2003-10-16

  Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: (I) wherein A, R1 , R2 , Rx , R8 , R9 and n are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

  式(I)或其药学上可接受的衍生物的化合物：其中A、R1、R2、Rx、R8、R9和n如规范中所定义，一种制备这种化合物的方法，包括这种化合物的药物组合物以及这种化合物在医学上的用途。
• [EN] HETEROCYCLYL COMPOUNDS<br/>[FR] COMPOSES HETEROCYCLYLE
  申请人：GLAXO GROUP LTD

  公开号：WO2005037786A1

  公开（公告）日：2005-04-28

  Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, B, D, Z, R1, R2a , R2b, and Rx are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in treating conditions mediated by the action of PGE2 at EP1 receptors. Such conditions include pain, or inflammatory, immunological, bone, neurodegenerative or renal disorders.

  式(I)的化合物或其药学上可接受的衍生物：其中A、B、D、Z、R1、R2a、R2b和Rx如规范中定义，制备这类化合物的方法，包含这类化合物的药物组合物以及利用这类化合物治疗由PGE2在EP1受体介导的疾病的用途。这些疾病包括疼痛、炎症、免疫、骨骼、神经退行性或肾脏疾病。
• [EN] CYCLOHEXENE COMPOUNDS<br/>[FR] CYCLOHEXENES
  申请人：GLAXO GROUP LTD

  公开号：WO2005037794A1

  公开（公告）日：2005-04-28

  Formula (I) wherein A, B, Z, R1, R2a , R2b, R8, R9 and Rx are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

  其中A、B、Z、R1、R2a、R2b、R8、R9和Rx如规范中定义的公式（I），一种制备这类化合物的方法，包括这类化合物的药物组合物以及这类化合物在医学上的用途。
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
  申请人：ASTRAZENECA AB

  公开号：WO2004089885A1

  公开（公告）日：2004-10-21

  The invention relates to substituted phenoxyacetic acids (I) as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.

  这项发明涉及取代苯氧乙酸(I)作为治疗呼吸系统疾病的有用药物化合物，包含它们的药物组合物，以及它们的制备方法。
• Synthesis and biological evaluation of (1,2,4)triazole[4,3-a]pyridine derivatives as potential therapeutic agents for concanavalin A-induced hepatitis
  作者：Yaojie Shi、Qianqian Wang、Juan Rong、Jing Ren、Xuejiao Song、Xiaoli Fan、Mengyi Shen、Yong Xia、Ningyu Wang、Zhihao Liu、Quanfang Hu、Tinghong Ye、Luoting Yu

  DOI：10.1016/j.ejmech.2019.06.025

  日期：2019.10

  A series of (1,2,4)triazole[4,3-a]pyridine (TZP) derivatives have been designed and synthesized. Compound 8d was identified as having the most potent inhibitory activity on NO release in response to lipopolysaccharide (LPS) stimulation and inhibition of the migration induced by MCP-1 protein on RAW264.7 macrophages. Based on the screening data, an immunofluorescence assay and a real-time qPCR assay

  已经设计和合成了一系列的（1,2,4）三唑[4,3-a]吡啶（TZP）衍生物。化合物8d被鉴定为对脂多糖（LPS）刺激具有最有效的抑制NO释放的活性，并抑制RAW264.7巨噬细胞上MCP-1蛋白诱导的迁移。基于筛选数据，进行了免疫荧光测定和实时qPCR测定，表明化合物8d通过伴刀豆球蛋白A（Con A）诱导的RAW264.7巨噬细胞抑制了NF-κBp65易位和炎性基因的表达。更重要的是8d还通过在小鼠自身免疫性肝炎（AIH）模型中下调血浆丙氨酸转氨酶（ALT），天冬氨酸转氨酶（AST）和炎性浸润的水平来缓解Con A诱导的肝炎。此外，流式细胞仪（FCM）数据表明化合物8d抑制了Con A诱导的小鼠肝脏中MDSC的积累。这些发现增加了化合物8d可能用作治疗AIH的潜在药物的可能性。